Only about half of physicians think their organization’s leaders are transparent, honest and make good decisions for patients and employees, according to a new report. To remedy this problem, the leaders of provider organizations must deploy more transparent communication lines with their physicians, as well as facilitate opportunities for physicians to nurture connections with their teams.
One in four providers said that health technology vendors haven’t kept their promises in the past year. KLAS Research debunked four common misconceptions vendors may have about why so many providers feel this way — such as the false notion that employees who weren't part of the purchasing decision feel the most disappointed by vendors or the misbelief that it's better to not make promises in the first place.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
As health systems roll out new patient-facing technologies, they need to ensure that their patients are comfortable using these tools. To avoid losing patient trust, hospitals should introduce new technology with transparency and patient education at the forefront of their minds, said Aaron Miri, Baptist Health's chief digital and information officer.
Panelists at HLTH's patient engagement track, hosted by MedCity News, zeroed in on three strategies for achieving patient centricity: building trust, engaging health navigators and providing easy-to-understand health information.
Infrequent communication about Covid-19 and slow adoption of virtual care were the most common reasons cited by patients when asked why they lost confidence in their doctor, according to the survey conducted by SymphonyRM.
Patients are not the only ones who will benefit from the price transparency rule — providers and payers can also gain competitive advantages as a result of the regulation. These include being able to deepen relationships with patients and support payment contract negotiations.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
A webinar from HealthSparq offers analysis on a consumer sentiment study on health plans. It offers some useful insights on how the public health crisis has laid bare the trust issues consumers have and how insurers can address them to the benefit of both.
As we work to help biopharmaceutical and healthcare companies integrate the voice...